Clinical Trials Logo
  1. Home
  2. Uveitis, Anterior
  3. NCT00404885

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis — LUMINATE  

Panuveitis Clinical Trial

Official title:
A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis

Clinical Trial Summary

The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00404885
Study type Interventional
Source Lux Biosciences, Inc.
Contact
Status Completed
Phase Phase 3
Start date January 2007
Completion date May 2009
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT03656692 - Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) Phase 4
Completed NCT02255032 - Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Phase 2
Recruiting NCT05101928 - Ozurdex Monotherapy Trial Phase 4
Completed NCT00167583 - Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Phase 3
Completed NCT02595398 - Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Phase 3
Recruiting NCT00407316 - Quality of Life and Visual Function in Uveitis Patients Phase 0
Completed NCT02746991 - Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis Phase 3
Recruiting NCT06085079 - Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study Phase 4
Completed NCT02725177 - Ocular Sarcoidosis Open Label Trial of ACTHAR Gel N/A
Completed NCT00908466 - Sirolimus as Therapeutic Approach to Uveitis Phase 1
Completed NCT00615693 - Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Phase 2
Completed NCT00404612 - A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Phase 3
Completed NCT00404742 - A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Phase 3
Completed NCT01789320 - Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Phase 1/Phase 2
Completed NCT02952001 - MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Completed NCT00407056 - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis Phase 3
Completed NCT00406887 - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Phase 3
Completed NCT03097315 - Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Phase 3